Drug intelligence / Profile preview

IM-PROVE I

Development stage: Unknown
Lead developer: Arbutus Biopharma
Modality: Small Molecules, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Oral, Subcutaneous

Overview

IM-PROVE I is an investigational combination regimen being developed by Arbutus Biopharma for the treatment of chronic hepatitis B virus (cHBV) infection. The regimen consists of imdusiran (AB-729), a subcutaneously administered GalNAc-conjugated small interfering RNA (siRNA) therapeutic, combined with pegylated interferon alfa-2a (an immunomodulator) and ongoing nucleos(t)ide analogue (NA) therapy. Imdusiran is designed to target hepatocytes and inhibit all HBV RNA transcripts, thereby reducing viral proteins and antigens (such as HBsAg) to help reawaken the host immune response. Pegylated interferon alfa-2a acts as an immunomodulator to boost the immune response, while the nucleos(t)ide analogue therapy suppresses viral replication. The combination is currently in Phase 2 clinical development, aiming to achieve a functional cure for chronic hepatitis B.

Other names: AB-729 + peginterferon alfa-2a + NAAB-729 + pegylated interferon alfa-2a + nucleos(t)ide analogueimdusiran + peginterferon alfa-2a + NAimdusiran + peginterferon alfa-2a + nucleos(t)ide analogueimdusiran + peginterferon alfa-2a + nucleos(t)ide analogue therapyimdusiran + pegylated interferon alfa-2a + NAimdusiran + pegylated interferon alfa-2a + nucleos(t)ide analogueimdusiran + pegylated interferon alfa-2a + nucleos(t)ide analogue therapy

Targets

HBV Pol (Hepatitis B virus polymerase)IFNAR (Immune system modulation via type I interferon receptor)ASGPR (Asialoglycoprotein Receptor 1)

Beyond the preview

Go deeper on IM-PROVE I.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IM-PROVE I.

Explore the full profile